Analyst Price Target is $5.00
▲ +54.80% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Gritstone bio in the last 3 months. The average price target is $5.00, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 54.80% upside from the last price of $3.23.
Current Consensus is
The current consensus among 3 investment analysts is to hold stock in Gritstone bio. This rating has held steady since August 2022, when it changed from a Buy consensus rating.
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.